SF1 and adrenal cortex carcinoma: Furthermore, an SF-1 synthetic inverse agonist prevents the increase in adrenocortical cell proliferation and the changes in hormone production induced by SF-1 overexpression in H295R cells, indicating that this transcription factor is a druggable target in ACC [105].